Denali Therapeutics (DNLI)
DNLIPrice: $22.47
Fair Value: 🔒
🔒score
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phas... more
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates... more
Description
Shares
| Market Cap | $3.56B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ryan J. Watts |
| IPO Date | 2017-12-08 | CAGR | — |
| Employees | 443 | Website | www.denalitherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DNLI chart loading...
Fundamentals
Technicals
| Enterprise Value | $3.82B | P/E Ratio | -7.57 |
| Forward P/E | -7.86 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 24083564785.3 |
| P/CF Ratio | -55933944907.14 | P/FCF Ratio | -46072860316.56 |
| EPS | $-2.97 | EPS Growth 1Y | 5.43% |
| EPS Growth 3Y | 18.29% | EPS Growth 5Y | 31.67% |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.46% | ROA | -0.47% |
| ROCE | -0.57% | Current Ratio | 9.79 |
| Quick Ratio | 9.79 | Cash Ratio | 1.01 |
| Debt/Equity | 0.05 | Interest Coverage | — |
| Altman Z Score | 12.63 | Piotroski Score | 2 |